Lumos Pharma, Inc. LUMO
Set alert
4.34 0.00 0.00%
At close · Dec 11
4.33 Day range 4.34
52-week range unavailable
- Open
- 4.33
- Prev close
- 4.34
- Mkt cap
- 37.54M
- Vol
- 390.87K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 4.33
- High
- 4.34
- Forward P/E
- -2.01
- Beta
- 0.33
- Short ratio
- 0.59
- Inst. own
- 24.27%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 7, 2024
- 50-d avg
- 4.23
- 200-d avg
- 3.10
- 1y target
- 4.25
Key statistics
- Market cap
- 37.54M
- Enterprise value
- 24.19M
- Trailing P/E
- 0.00
- Forward P/E
- -2.01
- PEG ratio
- 0.00
- Price / sales
- 17.02
- Price / book
- 7.64
- EPS (TTM)
- -4.28
- Beta
- 0.33
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 2.21M
- Revenue growth
- 10271.40%
- Free cash flow
- -19.43M
- Total cash
- 13.52M
- Total debt
- 172.00K
- Return on equity
- -172.83%
- Shares outstanding
- 8.65M
- Short % of float
- 0.87%
- 50-day average
- 4.23
- 200-day average
- 3.10
Analyst view
Consensus: buy
Buy
Price target (mean) 4.25
Ratings (0m) 2 1 buy · 1 hold · 0 sell
- Strong buy0
- Buy1
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 7, 2024
Expected Nov 7, 2024. Consensus EPS estimate -0.56.
Financials — quick view
LUMO Revenue — quarterly 726.00K
LUMO Net income — quarterly -7.47M
LUMO EPS — quarterly -0.90
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.56 | — | — | — |
| Aug 1, 2024 | Jun 1, 2024 | -1.26 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | -1.21 | — | — | — |
| Mar 7, 2024 | Dec 1, 2023 | -1.18 | — | — | — |
| Nov 7, 2023 | Sep 1, 2023 | -1.10 | — | — | — |
| Aug 9, 2023 | Jun 1, 2023 | -1.06 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 8, 2024 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Oct 24, 2024 | HC Wainwright & Co. | down | Buy | Neutral |
| Oct 23, 2024 | Jones Trading | down | Buy | Hold |
| Sep 27, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 24, 2024 | EF Hutton | init | — | Buy |
| Aug 2, 2024 | Oppenheimer | main | Outperform | Outperform |
About Lumos Pharma, Inc.
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease. Lumos Pharma, Inc. is headquartered in Austin, Texas. As of December 12, 2024, Lumos Pharma, Inc. was taken private.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- lumos-pharma.com
News
- Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures' Acquisition of Lumos Pharma
- SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Lumos Pharma Inc. – LUMO
- ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Lumos Pharma, Inc.
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MMLP and LUMO on Behalf of Shareholders
- LUMO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Lumos Pharma, Inc. Is Fair to Shareholders
- Lumos Pharma Announces Abstract Accepted for Oral Presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, APPES 2024
- Lumos Pharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference
- Lumos Pharma, Inc. (LUMO) Q2 2024 Earnings Call Transcript
- Lumos Pharma Reports Second Quarter 2024 Financial Results and Provides Clinical Development Update
- Lumos Pharma to Report Second Quarter 2024 Financial Results and Provide Clinical Update on August 1, 2024
Your note
Sign in to keep a note on LUMO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| HAWKINS RICHARD JAMES | Chief Executive Officer | Stock Award(Grant) | Mar 31, 2024 | 757,562 |
| KARPF DAVID B. M.D. | Officer | Stock Award(Grant) | Jan 31, 2023 | 8,294 |
| LAWLEY LORI D | Chief Financial Officer | Stock Award(Grant) | Mar 31, 2024 | 12,513 |
| MCKEW JOHN C | Officer | Sale | Aug 5, 2024 | 12,653 |
| PITUKCHEEWANONT PISIT DUKE M.D. | Officer | Stock Award(Grant) | Mar 31, 2024 | 16,930 |
| POWERS BRADLEY J | Officer | Stock Award(Grant) | Mar 31, 2024 | 6,334 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Private Advisor Group, LLC | 8.61% | 744,513 | 3.23M | Sep 29, 2024 |
| Goldman Sachs Group Inc | 4.19% | 362,198 | 1.57M | Sep 29, 2024 |
| Vanguard Group Inc | 2.82% | 244,082 | 1.06M | Sep 29, 2024 |
| Renaissance Technologies, LLC | 2.47% | 213,814 | 927.95K | Sep 29, 2024 |
| Jefferies Financial Group Inc. | 1.40% | 120,651 | 523.63K | Sep 29, 2024 |
| Greenwich Wealth Management Llc | 0.88% | 76,341 | 331.32K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.17% | 187,322 | 812.98K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.59% | 50,828 | 220.59K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.35% | 29,993 | 130.17K | Oct 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.22% | 18,744 | 81.35K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.11% | 9,129 | 39.62K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.10% | 8,658 | 37.58K | Oct 30, 2024 |